Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Depreciation & Amortization (CF) (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 54.25% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Dec 2025, up 43.37% year-over-year, with the annual reading at $11.2 million for FY2025, 43.37% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $2.9 million at Denali Therapeutics, down from $2.9 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $10.0 million in Q1 2023, with the low at $1.8 million in Q3 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $2.7 million, with a median of $2.2 million recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) surged 383.26% in 2023, then plummeted 78.48% in 2024.
  • Over 5 years, Depreciation & Amortization (CF) stood at $2.1 million in 2021, then surged by 94.72% to $4.1 million in 2022, then tumbled by 46.79% to $2.2 million in 2023, then decreased by 14.65% to $1.9 million in 2024, then surged by 54.25% to $2.9 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $2.9 million, $2.9 million, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.